Shopping Cart
- Remove All
- Your shopping cart is currently empty
Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $263 | In Stock | |
5 mg | $538 | In Stock | |
10 mg | $859 | In Stock | |
50 mg | $1,720 | In Stock | |
100 mg | $2,320 | In Stock |
Description | Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene. |
In vivo | In LmnaH222P/H222P mice, Emprumapimod (30 mg/kg; administered orally by gavage; starting at 16 weeks of age and continuing until 20 weeks of age) significantly increased left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD), while reducing FS, a parameter directly proportional to the left ventricular ejection fraction[1]. |
Alias | PF-07265803, ARRY-371797 |
Molecular Weight | 473.52 |
Formula | C24H29F2N5O3 |
Cas No. | 765914-60-1 |
Smiles | C(C(C)C)N1C=2C(=CC(OC3=C(F)C=C(F)C=C3)=C(C(N[C@@H](CCN(C)C)C(N)=O)=O)C2)C=N1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (168.95 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.